CEVMF yields 3.50% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, CEVMF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CEVMF + PFE for your $10,000?
CTS Eventim AG & Co. KGaA operates in the leisure events market in Germany, Italy, the United States, Switzerland, Austria, Finland, the Netherlands, Spain, and internationally. It operates through two segments, Ticketing and Live Entertainment. The Ticketing segment produces, sells, brokers, distributes, and markets tickets for concerts, theatre, art, sports, and other events. It markets events (tickets) through eventim.Web and using its network platform, EVENTIM.Net; in-house ticketing products through EVENTIM.Inhouse; sport ticketing products through EVENTIM.Tixx; and self-service products for promotors through EVENTIM.Light, as well as provides a solution for ticket sales and admission control through EVENTIM.Access. This segment also operates kinoheld software for cinema operators; EVENTIM.fanSALE, a resale portal where customers sell event tickets to other customers; and online portal under various brands, such as eventim.de, oeticket.com, ticketcorner.ch, ticketone.it, and entradas.com. The Live Entertainment segment plans, prepares, and performs tours, events, and festivals including music events and concerts, as well as markets music productions. This segment is also involved in the operation of venues. The company was formerly known as CTS EVENTIM AG and changed its name to CTS Eventim AG & Co. KGaA in May 2014. CTS Eventim AG & Co. KGaA was founded in 1989 and is headquartered in Bremen, Germany.
Full CEVMF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.